» Articles » PMID: 31534055

Alteration of Thyroid Hormone Signaling Triggers the Diabetes-induced Pathological Growth, Remodeling, and Dedifferentiation of Podocytes

Abstract

Thyroid hormone (TH) signaling is a universal regulator of metabolism, growth, and development. Here, we show that TH-TH receptor (TH-TR) axis alterations are critically involved in diabetic nephropathy-associated (DN-associated) podocyte pathology, and we identify TRα1 as a key regulator of the pathogenesis of DN. In ZSF1 diabetic rats, T3 levels progressively decreased during DN, and this was inversely correlated with metabolic and renal disease worsening. These phenomena were associated with the reexpression of the fetal isoform TRα1 in podocytes and parietal cells of both rats and patients with DN and with the increased glomerular expression of the TH-inactivating enzyme deiodinase 3 (DIO3). In diabetic rats, TRα1-positive cells also reexpressed several fetal mesenchymal and damage-related podocyte markers, while glomerular and podocyte hypertrophy was evident. In vitro, exposing human podocytes to diabetes milieu typical components markedly increased TRα1 and DIO3 expression and induced cytoskeleton rearrangements, adult podocyte marker downregulation and fetal kidney marker upregulation, the maladaptive cell cycle induction/arrest, and TRα1-ERK1/2-mediated hypertrophy. Strikingly, T3 treatment reduced TRα1 and DIO3 expression and completely reversed all these alterations. Our data show that diabetic stress induces the TH-TRα1 axis to adopt a fetal ligand/receptor relationship pattern that triggers the recapitulation of the fetal podocyte phenotype and subsequent pathological alterations.

Citing Articles

METTL10 attenuates adriamycin-induced podocyte injury by targeting cell dedifferentiation.

Bao J, Li Z, Yao H, Wu B, Gu L, Pan Y Sci Rep. 2025; 15(1):1218.

PMID: 39774961 PMC: 11707283. DOI: 10.1038/s41598-024-80526-8.


Losartan is more effective than angiotensin (1-7) in preventing thyroxine-induced renal injury in the rat.

Malatiali S, Oriowo M Thyroid Res. 2024; 17(1):22.

PMID: 39491028 PMC: 11533423. DOI: 10.1186/s13044-024-00211-w.


Iodothyronine Deiodinase 3 Gene Expression in Gastrointestinal Stromal Tumors: A Pilot Study to Contribute to Risk Assessment.

Kolcsar M, Zeces I, Kovecsi A, Kovacs Z, Gall Z Cureus. 2024; 16(8):e67426.

PMID: 39170648 PMC: 11338672. DOI: 10.7759/cureus.67426.


The predictive value of free thyroxine combined with tubular atrophy/interstitial fibrosis for poor prognosis in patients with IgA nephropathy.

Yang B, Zhou W, Cui L, Tian L, Ni Y, Yang M Front Endocrinol (Lausanne). 2024; 15:1372824.

PMID: 38808109 PMC: 11130362. DOI: 10.3389/fendo.2024.1372824.


Association of thyroid autoantibodies and diabetic kidney disease in hospitalised patients with type 2 diabetes mellitus: a cross-sectional study from a Chinese university hospital.

Wang Z, Wang F, Liu C, Zhang L BMJ Open. 2024; 14(3):e077338.

PMID: 38503411 PMC: 10952948. DOI: 10.1136/bmjopen-2023-077338.


References
1.
Santini F, Chiovato L, Ghirri P, Lapi P, Mammoli C, Montanelli L . Serum iodothyronines in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis. J Clin Endocrinol Metab. 1999; 84(2):493-8. DOI: 10.1210/jcem.84.2.5439. View

2.
Sweetwyne M, Gruenwald A, Niranjan T, Nishinakamura R, Strobl L, Susztak K . Notch1 and Notch2 in Podocytes Play Differential Roles During Diabetic Nephropathy Development. Diabetes. 2015; 64(12):4099-111. PMC: 4657584. DOI: 10.2337/db15-0260. View

3.
Pantos C, Xinaris C, Mourouzis I, Perimenis P, Politi E, Spanou D . Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"?. J Physiol Pharmacol. 2008; 59(2):253-69. View

4.
Cassis P, Cerullo D, Zanchi C, Corna D, Lionetti V, Giordano F . ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. Diabetes. 2018; 67(10):2069-2083. DOI: 10.2337/db17-1508. View

5.
Harder J, Menon R, Otto E, Zhou J, Eddy S, Wys N . Organoid single cell profiling identifies a transcriptional signature of glomerular disease. JCI Insight. 2019; 4(1). PMC: 6485369. DOI: 10.1172/jci.insight.122697. View